Pharmaceutical News RSS Feed - Pharmaceutical News

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015. [More]
Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Merus Labs International Inc. is pleased to announce that one of its wholly owned subsidiaries has signed a definitive agreement to acquire the rights to manufacture, market, and sell two established specialty pharmaceutical products in certain European and other markets. [More]
Chemical compound shows promise in treating rheumatoid arthritis

Chemical compound shows promise in treating rheumatoid arthritis

Montana State University researchers and their collaborators have published their findings about a chemical compound that shows potential for treating rheumatoid arthritis. [More]
Existing anti-stroke drug can be effective in treating middle-ear infections

Existing anti-stroke drug can be effective in treating middle-ear infections

An existing anti-stroke drug is an effective treatment for middle-ear infections, showing the ability to suppress mucus overproduction, improve bacterial clearance and reduce hearing loss, according to researchers at Georgia State University and the University of Rochester. [More]
ICS use may lower risk of mortality from pneumonia and other causes in COPD patients

ICS use may lower risk of mortality from pneumonia and other causes in COPD patients

Treatment of COPD with inhaled corticosteroids (ICS) may decrease the risk of dying from pneumonia and from other causes despite being associated with an increase in the occurrence of pneumonia, according to a new meta-analysis presented at the 2015 American Thoracic Society International Conference. [More]
Canada lagging behind similar OECD countries with regard to public drug plan reimbursement

Canada lagging behind similar OECD countries with regard to public drug plan reimbursement

Canadians face wait times of over 460 days in order to get access to new, potentially lifesaving medicines in public drug plans, according to a new IMS Brogan report commissioned by Rx&D. Overall, the report ranks Canada 16 out of 18 similar OECD countries. [More]
FDA accepts Tris Pharma's Dyanavel XR NDA for review

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension. [More]
Enterprise Therapeutics secures additional funding to accelerate drug discovery for treatment of respiratory diseases

Enterprise Therapeutics secures additional funding to accelerate drug discovery for treatment of respiratory diseases

ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured an additional £2.4m ($3.6m) in Series-A financing. [More]
Second-generation antibiotic shows promise against common bacterial infections

Second-generation antibiotic shows promise against common bacterial infections

Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults. [More]
HQO report shows variations across Ontario's long-term care homes regarding antipsychotic drug use

HQO report shows variations across Ontario's long-term care homes regarding antipsychotic drug use

There are major differences across Ontario's long-term care homes in the percentage of residents who are being prescribed antipsychotic medications, according to Looking for Balance, a report from Health Quality Ontario, the provincial advisor on health care quality. [More]
New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

Clinical experience of biosimilar infliximab in 78 inflammatory bowel disease (IBD) patients presented at Digestive Diseases Week (DDW) 2015 in Washington D.C. showed that the treatment is comparable to the reference medicinal product (RMP) in terms of efficacy and safety. [More]
Omega-3 fatty acids improve cognitive flexibility in older adults at risk of late-onset Alzheimer's disease

Omega-3 fatty acids improve cognitive flexibility in older adults at risk of late-onset Alzheimer's disease

A study of older adults at risk of late-onset Alzheimer's disease found that those who consumed more omega-3 fatty acids did better than their peers on tests of cognitive flexibility -- the ability to efficiently switch between tasks -- and had a bigger anterior cingulate cortex, a brain region known to contribute to cognitive flexibility. [More]
New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

A new study by UCLA researchers has found that Naltrexone, a drug used to treat alcoholism, may also be a promising treatment for addiction to methamphetamine. [More]
Twin Cities Orthopedics joins Deterra partnership program to reduce prescription drug abuse and misuse

Twin Cities Orthopedics joins Deterra partnership program to reduce prescription drug abuse and misuse

Verde Technologies announced that Golden Valley-based Twin Cities Orthopedics, the largest orthopedic group in Minnesota, has become its most recent partner in the fight against prescription drug abuse and misuse. [More]
Short course of oral steroids unlikely to provide much benefit for patients with acute sciatica

Short course of oral steroids unlikely to provide much benefit for patients with acute sciatica

Among patients with acute sciatica caused by a herniated lumbar disk (a condition also known as "acute radiculopathy"), a short course of oral steroids resulted in only modest improvement in function and no significant improvement in pain, according to a study published today in the Journal of the American Medical Association. [More]
Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, the bacteria responsible for the chronic lung infection tuberculosis. [More]
Current menopausal hormone therapy users at increased risk of experiencing GI bleeding

Current menopausal hormone therapy users at increased risk of experiencing GI bleeding

Current users of menopausal hormone therapy (MHT) are more than twice as likely than non-users to develop lower gastrointestinal bleeding and ischemic colitis, especially if they use the therapy for longer durations, according to a study at Digestive Disease Week 2015. [More]
Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility. [More]
Two-drug combination improves lung function in some cystic fibrosis patients

Two-drug combination improves lung function in some cystic fibrosis patients

The combination of two drugs — an investigational drug used in conjunction with an already FDA-approved medication — improved lung function in patients with one form of cystic fibrosis, according to two new studies. [More]
BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform. [More]
Advertisement
Advertisement